gene therapy
Bluebird Bio’s Fall from Grace: Gene Therapy Pioneer Sells for $29M After $10B Valuation
Bluebird Bio, gene therapy, private equity, Carlyle, SK Capital, financial challenges, acquisition, biotech industry
Solid Biosciences’ DMD Gene Therapy Shows Promising Early Results, Driving Stock Surge
Duchenne muscular dystrophy (DMD), gene therapy, SGT-003, microdystrophin, clinical trial, stock surge, Solid Biosciences
Voyager Therapeutics Halts ALS Gene Therapy Development Due to Off-Target Effects
SOD1 ALS gene therapy, Off-target effects, VY9323, siRNA payload, TRACER capsid, Preclinical data, Drug development delay
NHS England Approves Groundbreaking CRISPR Gene Therapy for Sickle Cell Disease
Casgevy, exagamglogene autotemcel, CRISPR gene therapy, sickle cell disease, NHS England, Vertex Pharmaceuticals, NICE approval
Rentschler Biopharma Exits Cell and Gene Therapy Sector, Refocuses on Biologics Manufacturing
Rentschler Biopharma, strategic realignment, cell and gene therapy, biologics manufacturing, CDMO, market demand, Stevenage facility closure
Sarepta Therapeutics Reports Encouraging Two-Year Data for ELEVIDYS in Duchenne Muscular Dystrophy, Projecting $1 Billion in Sales
Sarepta Therapeutics, ELEVIDYS, Duchenne Muscular Dystrophy (DMD), Gene Therapy, Clinical Trial Results, Sales Projections
Tune Therapeutics Secures $175M in Series B Funding to Advance Epigenome Editing Programs
Epigenome editing, Tune Therapeutics, Series B funding, Hepatitis B treatment, Gene therapy, Biotech investment
RegenXBio Secures $110M Upfront in Strategic Partnership with Nippon Shinyaku for Hunter Syndrome Gene Therapy
RegenXBio, Hunter syndrome, Gene therapy, Nippon Shinyaku, Strategic partnership, Rare metabolic disorder, Mucopolysaccharidosis type II (MPS II), RGX-121, RGX-111
Tune Therapeutics Secures $175M to Advance Epigenetic Editing into Clinical Trials
Epigenetic editing, gene therapy, Tune Therapeutics, clinical trials, biotech funding
National Resilience Lays Off 120 Employees at Former Bluebird Bio Gene Therapy Facility in Durham, North Carolina
National Resilience, Layoffs, Gene Therapy, Bluebird Bio, Durham/ North Carolina, Biotech Industry, CDMO (Contract Development and Manufacturing Organization)